GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Operating Cash Flow per Share

MedMira (MedMira) Operating Cash Flow per Share : $-0.00 (TTM As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Operating Cash Flow per Share?

MedMira's operating cash flow per share for the three months ended in Jan. 2024 was $-0.00. MedMira's operating cash flow per share for the trailing twelve months (TTM) ended in Jan. 2024 was $-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for MedMira's Operating Cash Flow per Share or its related term are showing as below:

During the past 13 years, MedMira's highest 3-Year average Operating Cash Flow per Share Growth Rate was 52.10% per year. The lowest was -44.20% per year. And the median was 29.10% per year.

MMIRF's 3-Year OCF Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

MedMira Operating Cash Flow per Share Historical Data

The historical data trend for MedMira's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Operating Cash Flow per Share Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MedMira's Operating Cash Flow per Share

For the Biotechnology subindustry, MedMira's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where MedMira's Price-to-Operating-Cash-Flow falls into.



MedMira Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

MedMira's Operating Cash Flow per Share for the fiscal year that ended in Jul. 2023 is calculated as

Operating Cash Flow per Share (A: Jul. 2023 )=Cash Flow from Operations (A: Jul. 2023 )/Shares Outstanding (Diluted Average) (A: Jul. 2023 )
=-0.96/697.446
=-0.00

MedMira's Operating Cash Flow per Share for the quarter that ended in Jul. 2023 is calculated as

Operating Cash Flow per Share (Q: Jan. 2024 )=Cash Flow from Operations (Q: Jan. 2024 )/Shares Outstanding (Diluted Average) (Q: Jan. 2024 )
=-0.402/698.088
=-0.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of MedMira's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Industry
Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 12-01-2021

MedMira Reports First Quarter Results FY2021

By GlobeNewswire GlobeNewswire 12-25-2020

MedMira Reports First Quarter Results FY2020

By GlobeNewswire GlobeNewswire 12-31-2019

MedMira Reports Third Quarter Results FY2022

By GlobeNewswire GlobeNewswire 06-30-2022

MedMira Closes New Equity Investment for Future Growth

By GlobeNewswire GlobeNewswire 07-15-2021

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023

MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

By ACCESSWIRE ACCESSWIRE 10-14-2022

MedMira Reports Second Quarter Results

By GlobeNewswire GlobeNewswire 03-30-2018

MedMira Reports First Quarter Results FY2022

By GlobeNewswire GlobeNewswire 12-31-2021